Free shipping on all orders over $ 500

Vistusertib

Cat. No. M2299

All AbMole products are for research use only, cannot be used for human consumption.

Vistusertib Structure
Synonym:

AZD2014

Size Price Availability Quantity
5mg USD 80 In stock
10mg USD 135 In stock
25mg USD 225 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Vistusertib (AZD2014) is a novel dual mTORC1 and mTORC2 inhibitor with potential antineoplastic activity. Vistusertib (AZD2014) inhibits biomarkers pAKTSer473 and pNDRG1Thr346. Vistusertib (AZD2014)  has broad antiproliferative activity across multiple tumour cell lines. Vistusertib (AZD2014) induces growth inhibition and cell death in breast cancer cell lines, including ER+ cell lines with acquired resistance to hormone therapy. Vistusertib (AZD2014) induces tumour growth inhibition against several xenograft models including a human primary explant model of ER+ breast cancer refractory to tamoxifen.

Customer Product Validations & Biological Datas
Source Cell Physiol Biochem (2018). Figure 4. AZD2014
Method Flow cytometric analysis
Cell Lines NSCLC cell
Concentrations -
Incubation Time 24 h
Results When mTOR was inhibited in anti-miR-99a-A549 cells by AZD2014, the cells became more sensitive to radiation than control cells and the levels of anti-apoptosis markers were reduced
Chemical Information
Molecular Weight 462.54
Formula C25H30N6O3
CAS Number 1009298-59-2
Solubility (25°C) DMSO 18 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Byung-Hyun Cha, et al. AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo

[2] Ruyu Pi, et al. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth

[3] H Liao, et al. Antitumor effects of AZD2014, a dual mTORC1/2 inhibitor, against human hepatocellular carcinoma xenograft in nude mice

[4] Julien Bensalem, et al. Inhibiting mTOR activity using AZD2014 increases autophagy in the mouse cerebral cortex

[5] Senmao Li, et al. Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells

Related mTOR Products
AZD8055

AZD8055 is a novel ATP-competitive inhibitor of mTOR kinase (both complexes mTORC1 and mTORC2) with an IC50 of 0.8 nM.

Deforolimus

Deforolimus (also known as AP23573 and MK-8669) is an investigational targeted and small-molecule mTOR inhibitor. *The compound is unstable in solutions, freshly prepared is recommended

Everolimus

Everolimus (RAD001) also known as SDZ-RAD and Certican is an mTOR inhibitor with IC50 of 0.63 nM.

KU-0063794

KU-0063794 is a potent and selective mTOR inhibitor with IC50 values of approximately 10 nM for mTORC1 and mTORC2.

WYE-354

WYE-354 is a cell-permeable pyrazolopyrimidine compound that acts as a potent and ATP-competitive mTOR inhibitor (IC50 = 5 nM with S6K as the substrate and 100 µM ATP).

  Catalog
Abmole Inhibitor Catalog




Keywords: Vistusertib, AZD2014 supplier, mTOR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.